Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies

Alida Ault; Alyse M. Zajac; Wing Pui Kong; J. Patrick Gorres; Michael Royals; Chih Jen Wei; Saran Bao; Zhi yong Yang; Stephanie E. Reedy; Tracy L. Sturgill; Allen E. Page; Jennifer Donofrio-Newman; Amanda A. Adams; Udeni B.R. Balasuriya; David W. Horohov; Thomas M. Chambers; Gary J. Nabel; Srinivas S. Rao

doi:10.1016/j.vaccine.2012.03.026

Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies

Alida Ault
, Alyse M. Zajac
, Wing Pui Kong
, J. Patrick Gorres
, Michael Royals
, Chih Jen Wei
, Saran Bao
, Zhi yong Yang
, Stephanie E. Reedy
, Tracy L. Sturgill
, Allen E. Page
, Jennifer Donofrio-Newman
, Amanda A. Adams
, Udeni B.R. Balasuriya
, David W. Horohov
, Thomas M. Chambers
, Gary J. Nabel
, Srinivas S. Rao

Veterinary Science

Producción científica: Article › revisión exhaustiva

36 Citas (Scopus)

Resumen

Equine influenza A (H3N8) virus infection is a leading cause of respiratory disease in horses, resulting in widespread morbidity and economic losses. As with influenza in other species, equine influenza strains continuously mutate, often requiring the development of new vaccines. Current inactivated (killed) vaccines, while efficacious, only offer limited protection against diverse subtypes and require frequent boosts. Research into new vaccine technologies, including gene-based vaccines, aims to increase the neutralization potency, breadth, and duration of protective immunity. Here, we demonstrate that a DNA vaccine expressing the hemagglutinin protein of equine H3N8 influenza virus generates homologous and heterologous immune responses, and protects against clinical disease and viral replication by homologous H3N8 virus in horses. Furthermore, we demonstrate that needle-free delivery is as efficient and effective as conventional parenteral injection using a needle and syringe. These findings suggest that DNA vaccines offer a safe, effective, and promising alternative approach for veterinary vaccines against equine influenza.

Idioma original	English
Páginas (desde-hasta)	3965-3974
Número de páginas	10
Publicación	Vaccine
Volumen	30
N.º	26
DOI	https://doi.org/10.1016/j.vaccine.2012.03.026
Estado	Published - jun 6 2012

Nota bibliográfica

Funding Information:
We thank the University of Kentucky Veterinary Science farm crew for their expert animal care and handling. We also gratefully acknowledge the contributions of Ms. Judy Stein for material transfer and contractual requirements; Ms. Brenda Hartman for figure formatting; Ms. Martha Nason for assistance with statistical analysis; and Dr. Mythreyi Shastri for manuscript preparation. To fully disclose any potential conflicts of interest, authors Gary J. Nabel, Srinivas S. Rao, Wing-Pui Kong, Zhi-Yong Yang and Chih-Jen Wei are each listed on a patent filing for our DNA vaccine technology, entitled “U.S. Continuation in Part Patent Application No. 12/838,292″, which is an adjunct to an existing patent entitled “Influenza DNA Vaccination and Methods of Use thereof”, Serial #61/023,341. This research was supported by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health and by the Kentucky Agricultural Experiment Station (project no. KY014041).

Financiación

We thank the University of Kentucky Veterinary Science farm crew for their expert animal care and handling. We also gratefully acknowledge the contributions of Ms. Judy Stein for material transfer and contractual requirements; Ms. Brenda Hartman for figure formatting; Ms. Martha Nason for assistance with statistical analysis; and Dr. Mythreyi Shastri for manuscript preparation. To fully disclose any potential conflicts of interest, authors Gary J. Nabel, Srinivas S. Rao, Wing-Pui Kong, Zhi-Yong Yang and Chih-Jen Wei are each listed on a patent filing for our DNA vaccine technology, entitled “U.S. Continuation in Part Patent Application No. 12/838,292″, which is an adjunct to an existing patent entitled “Influenza DNA Vaccination and Methods of Use thereof”, Serial #61/023,341. This research was supported by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health and by the Kentucky Agricultural Experiment Station (project no. KY014041).

Financiadores	Número del financiador
US National Institutes of Health/NHGRI
Center for Infectious Disease and Vaccine Research La Jolla Institute for Immunology (LJI)
National Institute of Allergy and Infectious Diseases	ZIAAI005003
Kentucky Agricultural Experiment Station

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Acceder al documento

10.1016/j.vaccine.2012.03.026

Otros archivos y enlaces

Citar esto

Ault, A., Zajac, A. M., Kong, W. P., Gorres, J. P., Royals, M., Wei, C. J., Bao, S., Yang, Z. Y., Reedy, S. E., Sturgill, T. L., Page, A. E., Donofrio-Newman, J., Adams, A. A., Balasuriya, U. B. R., Horohov, D. W., Chambers, T. M., Nabel, G. J., & Rao, S. S. (2012). Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies. Vaccine, 30(26), 3965-3974. https://doi.org/10.1016/j.vaccine.2012.03.026

@article{168d16e1688d4b3e839ef38f6bf27e30,

title = "Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies",

abstract = "Equine influenza A (H3N8) virus infection is a leading cause of respiratory disease in horses, resulting in widespread morbidity and economic losses. As with influenza in other species, equine influenza strains continuously mutate, often requiring the development of new vaccines. Current inactivated (killed) vaccines, while efficacious, only offer limited protection against diverse subtypes and require frequent boosts. Research into new vaccine technologies, including gene-based vaccines, aims to increase the neutralization potency, breadth, and duration of protective immunity. Here, we demonstrate that a DNA vaccine expressing the hemagglutinin protein of equine H3N8 influenza virus generates homologous and heterologous immune responses, and protects against clinical disease and viral replication by homologous H3N8 virus in horses. Furthermore, we demonstrate that needle-free delivery is as efficient and effective as conventional parenteral injection using a needle and syringe. These findings suggest that DNA vaccines offer a safe, effective, and promising alternative approach for veterinary vaccines against equine influenza.",

keywords = "DNA vaccine, Equine, Immunogenicity, Influenza, Protection",

author = "Alida Ault and Zajac, \{Alyse M.\} and Kong, \{Wing Pui\} and Gorres, \{J. Patrick\} and Michael Royals and Wei, \{Chih Jen\} and Saran Bao and Yang, \{Zhi yong\} and Reedy, \{Stephanie E.\} and Sturgill, \{Tracy L.\} and Page, \{Allen E.\} and Jennifer Donofrio-Newman and Adams, \{Amanda A.\} and Balasuriya, \{Udeni B.R.\} and Horohov, \{David W.\} and Chambers, \{Thomas M.\} and Nabel, \{Gary J.\} and Rao, \{Srinivas S.\}",

note = "Funding Information: We thank the University of Kentucky Veterinary Science farm crew for their expert animal care and handling. We also gratefully acknowledge the contributions of Ms. Judy Stein for material transfer and contractual requirements; Ms. Brenda Hartman for figure formatting; Ms. Martha Nason for assistance with statistical analysis; and Dr. Mythreyi Shastri for manuscript preparation. To fully disclose any potential conflicts of interest, authors Gary J. Nabel, Srinivas S. Rao, Wing-Pui Kong, Zhi-Yong Yang and Chih-Jen Wei are each listed on a patent filing for our DNA vaccine technology, entitled “U.S. Continuation in Part Patent Application No. 12/838,292″, which is an adjunct to an existing patent entitled “Influenza DNA Vaccination and Methods of Use thereof”, Serial \#61/023,341. This research was supported by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health and by the Kentucky Agricultural Experiment Station (project no. KY014041). ",

year = "2012",

month = jun,

day = "6",

doi = "10.1016/j.vaccine.2012.03.026",

language = "English",

volume = "30",

pages = "3965--3974",

number = "26",

}

Ault, A, Zajac, AM, Kong, WP, Gorres, JP, Royals, M, Wei, CJ, Bao, S, Yang, ZY, Reedy, SE, Sturgill, TL, Page, AE, Donofrio-Newman, J, Adams, AA, Balasuriya, UBR, Horohov, DW, Chambers, TM, Nabel, GJ & Rao, SS 2012, 'Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies', Vaccine, vol. 30, n.º 26, pp. 3965-3974. https://doi.org/10.1016/j.vaccine.2012.03.026

TY - JOUR

T1 - Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies

AU - Ault, Alida

AU - Zajac, Alyse M.

AU - Kong, Wing Pui

AU - Gorres, J. Patrick

AU - Royals, Michael

AU - Wei, Chih Jen

AU - Bao, Saran

AU - Yang, Zhi yong

AU - Reedy, Stephanie E.

AU - Sturgill, Tracy L.

AU - Page, Allen E.

AU - Donofrio-Newman, Jennifer

AU - Adams, Amanda A.

AU - Balasuriya, Udeni B.R.

AU - Horohov, David W.

AU - Chambers, Thomas M.

AU - Nabel, Gary J.

AU - Rao, Srinivas S.

N1 - Funding Information: We thank the University of Kentucky Veterinary Science farm crew for their expert animal care and handling. We also gratefully acknowledge the contributions of Ms. Judy Stein for material transfer and contractual requirements; Ms. Brenda Hartman for figure formatting; Ms. Martha Nason for assistance with statistical analysis; and Dr. Mythreyi Shastri for manuscript preparation. To fully disclose any potential conflicts of interest, authors Gary J. Nabel, Srinivas S. Rao, Wing-Pui Kong, Zhi-Yong Yang and Chih-Jen Wei are each listed on a patent filing for our DNA vaccine technology, entitled “U.S. Continuation in Part Patent Application No. 12/838,292″, which is an adjunct to an existing patent entitled “Influenza DNA Vaccination and Methods of Use thereof”, Serial #61/023,341. This research was supported by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health and by the Kentucky Agricultural Experiment Station (project no. KY014041).

PY - 2012/6/6

Y1 - 2012/6/6

N2 - Equine influenza A (H3N8) virus infection is a leading cause of respiratory disease in horses, resulting in widespread morbidity and economic losses. As with influenza in other species, equine influenza strains continuously mutate, often requiring the development of new vaccines. Current inactivated (killed) vaccines, while efficacious, only offer limited protection against diverse subtypes and require frequent boosts. Research into new vaccine technologies, including gene-based vaccines, aims to increase the neutralization potency, breadth, and duration of protective immunity. Here, we demonstrate that a DNA vaccine expressing the hemagglutinin protein of equine H3N8 influenza virus generates homologous and heterologous immune responses, and protects against clinical disease and viral replication by homologous H3N8 virus in horses. Furthermore, we demonstrate that needle-free delivery is as efficient and effective as conventional parenteral injection using a needle and syringe. These findings suggest that DNA vaccines offer a safe, effective, and promising alternative approach for veterinary vaccines against equine influenza.

AB - Equine influenza A (H3N8) virus infection is a leading cause of respiratory disease in horses, resulting in widespread morbidity and economic losses. As with influenza in other species, equine influenza strains continuously mutate, often requiring the development of new vaccines. Current inactivated (killed) vaccines, while efficacious, only offer limited protection against diverse subtypes and require frequent boosts. Research into new vaccine technologies, including gene-based vaccines, aims to increase the neutralization potency, breadth, and duration of protective immunity. Here, we demonstrate that a DNA vaccine expressing the hemagglutinin protein of equine H3N8 influenza virus generates homologous and heterologous immune responses, and protects against clinical disease and viral replication by homologous H3N8 virus in horses. Furthermore, we demonstrate that needle-free delivery is as efficient and effective as conventional parenteral injection using a needle and syringe. These findings suggest that DNA vaccines offer a safe, effective, and promising alternative approach for veterinary vaccines against equine influenza.

KW - DNA vaccine

KW - Equine

KW - Immunogenicity

KW - Influenza

KW - Protection

UR - https://www.scopus.com/pages/publications/84861199412

UR - https://www.scopus.com/pages/publications/84861199412#tab=citedBy

U2 - 10.1016/j.vaccine.2012.03.026

DO - 10.1016/j.vaccine.2012.03.026

M3 - Article

C2 - 22449425

AN - SCOPUS:84861199412

SN - 0264-410X

VL - 30

SP - 3965

EP - 3974

JO - Vaccine

JF - Vaccine

IS - 26

ER -

Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto